12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Company News  |  Deals

Newron, Zambon deal

Zambon exercised its option to license exclusive rights to develop and commercialize Newron's safinamide worldwide, excluding Asian territories where Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) has rights. Last month, Zambon paid €5 million ($6.4 million) for the option and a 9.1%...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >